| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | Director, 10% Owner
3 companies
Broadwood Partners, L.P. serves as a Director, 10% Owner at LCTX and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 312 buys and 56 sells. Those positions are worth an estimated $489.9M at current prices.
Historically, Broadwood Partners, L.P.'s trades have earned a middling insider score of 61/100 across 93 rated trades. Over a 12-month horizon, 53.8% of those trades were profitable, with an average 12-month return of +8.3%.
The biggest single holding is STAA (~$374.1M) as 10% Owner. Net of sales, the recent Form 4 record there shows accumulation of 7,713,553 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 20, 2016 | LCTX Lineage Cell Therapeutics, Inc. | Director, 10% Owner | Buy | 300,000 | $2.35 | $705,000.00 | +0.7% | |
| Jan 20, 2016 | STAA Staar Surgical Co | 10% Owner | Buy | 72,858 | $6.75 | $491,620.98 | +0.2% | |
| Jan 15, 2016 | STAA Staar Surgical Co | 10% Owner | Buy | 135,725 | $6.73 | $913,178.51 | +0.2% | |
| Jan 11, 2016 | STAA Staar Surgical Co | 10% Owner | Buy | 86,586 | $6.83 | $591,485.07 | +0.2% | |
| Jan 7, 2016 | STAA Staar Surgical Co | 10% Owner | Buy | 267,047 | $6.95 | $1,856,079.29 | +0.5% | |
| Jan 4, 2016 | STAA Staar Surgical Co | 10% Owner | Buy | 165,461 | $7.11 | $1,176,187.92 | +0.3% | |
| Sep 29, 2015 | STAA Staar Surgical Co | 10% Owner | Buy | 311,099 | $7.08 | $2,203,748.70 | +0.6% | |
| Aug 25, 2015 | STAA Staar Surgical Co | 10% Owner | Buy | 188,881 | $7.17 | $1,354,241.46 | +0.4% |